Expression of tyrosine hydroxylase increases the resistance of human neuroblastoma cells to oxidative insults

Toxicological Sciences

Volumn 113, Issue 1, 2009, Pages 150-157

  Franco, Jeferson L ^a   Posser, Thaís ^b   Gordon, Sarah L ^c   Bobrovskaya, Larisa ^c   Schneider, Jennifer J ^c   Farina, Marcelo ^b   Dafre, Alcir L ^b   Dickson, Phillip W ^c   Dunkley, Peter R ^c  

^a UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Dopamine; Glutathione peroxidase; Glutathione reductase; Oxidative stress; Tyrosine hydroxylase

Indexed keywords

CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; ISOENZYME; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DATA ANALYSIS; DETOXIFICATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; OXIDATION; PROTEIN EXPRESSION;

APOPTOSIS; CARMUSTINE; CATALASE; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HUMANS; HYDROGEN PEROXIDE; NEUROBLASTOMA; OXIDATIVE STRESS; OXIDOPAMINE; THIOMALATES; TRANSFECTION; TYROSINE 3-MONOOXYGENASE;

EID: 75249102417     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp245     Document Type: Article

References (46)

1. Aebi, H. (1984). Catalase in vitro. Methods Enzymol. 105, 121-126.
2. Andoh, T., and Chiueh, C.C. (2002). Preconditioning-mediated neuroprotection: role of nitric oxide, cGMP, and new protein expression. Ann. N.Y. Acad. Sci. 962, 1-7.
3. Bobrovskaya, L., Gilligan, C., Bolster, E.K., Flaherty, J.J., and Dunkley, P.R. (2007). Sustained phosphorylation of tyrosine hydroxylase at serine 40: a novelmechanism for maintenance of catecholamine synthesis. J. Neurochem. 100, 479-489.
4. Calabrese, E.J. (2008). Pharmacological enhancement of neuronal survival. Crit. Rev. Toxicol. 38, 349-389.
5. Cannon, J.R., Keep, R.F., Hua, Y., Richardson, R.J., and Xi, G. (2005). Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. Neurosci. Lett. 373, 189-194.
6. Carlberg, I., and Mannervik, B. (1985). Glutathione reductase. Methods Enzymol. 113, 484-490.
7. Casado, A., Encarnacion Lopez-Fernandez, M., and de La Torre, R. (2008). Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem. Res. 33, 450-458.
8. Dringen, R., and Hamprecht, B. (1998). Detoxification of exogenous hydrogen peroxide and organic hydroperoxides by cultured astroglial cells assessed by microtiter plate assay. Brain Res. Brain Res. Protoc. 2, 223-228.
9. Dringen, R., and Hirrlinger, J. (2005). Peroxide detoxification by brain cells. J. Neurosci. Res. 79, 157-165.
10. Dunkley, P.R., Bobrovskaya, L., Graham, M.E., and Dickson, P.W. (2004). Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 91, 1025-1043.
11. During, M.J., Naegele, J.R., and Geller, A.I. (1994). Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399-1403.
12. Fisher, L.J., Jinnah, H.A., Kale, L.C., and Gage, F.H. (1991). Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371-380.
13. Franco, J.L., Posser, T., Brocardo, P.S., Trevisan, R., Uliano-Silva, M., Gabilan, N.H., Santos, A.R., Leal, R.B., Rodrigues, A.L., Farina, M., et al. (2008). Involvement of glutathione, ERK1/2 phosphorylation and BDNF expression in the antidepressant-like effect of zinc in rats. Behav. Brain Res. 188, 316-323.
14. Gordon, S.L., Bobrovskaya, L., Dunkley, R.P., and Dickson, P.W. (2009). Differential regulation of human tyrosine hydroxylase isoforms 1 and 2 in situ: isoform 2 is not phosphorylated at Ser35. Biochim. Biophys. Acta. Advance Access published on October 13, 2009.
15. Guerrero-Cazares, H., Alatorre-Carranza Mdel, P., Delgado-Rizo, V., Duenas-Jimenez, J.M., Mendoza-Magana, M.L., Morales-Villagran, A., Ramirez-Herrera, M.A., Guerrero-Hernandez, A., and Duenas-Jimenez, S.H. (2007). Dopamine release modifies intracellular calcium levels in tyrosine hydroxylase-transfected C6 cells. Brain Res. Bull. 74, 113-118.
16. Halliwell, B. (1992). Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
17. Hastings, T.G. (1995). Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64, 919-924.
18. Hastings, T.G., and Zigmond, M.J. (1997). Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural. Transm. Suppl. 49, 103-110.
19. Lehmann, I.T., Bobrovskaya, L., Gordon, S.L., Dunkley, P.R., and Dickson, P.W. (2006). Differential regulation of the human tyrosine hydroxylase isoforms via hierarchical phosphorylation. J. Biol. Chem. 281, 17644-17651.
20. Ishida, A., and Yasuzumi, F. (2000). Approach to ex vivo gene therapy in the treatment of Parkinson's disease. Brain Dev. 22(Suppl. 1), S143-S147.
21. Jia, Z., Zhu, H., Misra, B.R., and Misra, H.P. (2008). Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection. Neurochem. Res. 33, 2197-2205.
22. Jiao, S., and Wolff, J.A. (1993). Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 362, 450-453.
23. Jingzhong, Z., Hui, Y., Deyi, D., Chunli, D., Chunli, Z., Xiaohong, S., and Qunyuan, X. (2005). Long-term therapeutic effects on parkinsonian rats of intrastriatal co-grafts with genetically engineered fibroblasts expressing tyrosine hydroxylase and glial cell line-derived neurotrophic factor. Int. J. Neurosci. 115, 769-779.
24. Kim, S.Y., and Lee, K.Y. (2008). A novel function of peroxiredoxin 1 (Prx-1) in apoptosis signal-regulating kinase 1 (ASK1)-mediated signaling pathway. FEBS Lett. 582, 1913-1918.
25. Latchman, D.S. (2005). HSP27 and cell survival in neurones. Int. J. Hyperthermia 21, 393-402.
26. Lazou, A., Markou, T., Zioga, M., Vasara, E., and Gaitanaki, C. (2006). Dopamine mimics the cardioprotective effect of ischemic preconditioning via activation of alpha1-adrenoceptors in the isolated rat heart. Physiol. Res. 55, 1-8.
27. Leak, R.K., and Zigmond, M.J. (2006). Effect of sublethal 6-hydroxydopamine on the response to subsequent oxidative stress in dopaminergic cells: evidence for preconditioning. J. Neurochem. 99, 1151-1163.
28. Locke, C.J., Fox, S.A., and Caldwell, K.A. (2008). Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. Neurosci. Lett. 439, 129-133.
29. Lundberg, C., Horellou, P., and Bjorklund, A. (1996). Generation of DOPA producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp. Neurol. 139, 39-53.
30. Mazzulli, J.R., Mishizen, A.J., Giasson, B.I., Lynch, D.R., Thomas, S.A., Nakashima, A., Nagatsu, T., and Ischiropoulos, H. (2006). Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068-10078.
31. McCormack, A.L., Atienza, J.G., Langston, J.W., and Di Monte, D.A. (2006). Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 141, 929-937.
32. McCoy, M.K., Ruhn, K.A., Martinez, T.N., McAlpine, F.E., and Tansey, M.G. (2008). Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol. Ther. 16, 1572-1579.
33. Medeiros, R., Prediger, R.D., Passos, G.F., Pandolfo, P., Duarte, F.S., Franco, J.L., Dafre, A.L., Di Giunta, G., Figueiredo, C.P., Takahashi, R.N., et al. (2007). Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci. 27, 5394-5404.
34. Miyazaki, I., and Asanuma, M. (2008). Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med. Okayama 62, 141-150.
35. Nicoletti, I., Migliorati, G., Pagliacci, M.C., and Riccardi, C. (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271-279.
36. Otani, H. (2004). Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid. Redox Signal. 6, 449-469.
37. Park, H.J., Lee, P.H., Bang, O.Y., and Ahn, Y.H. (2008). Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J. Neurochem. 107, 141-151.
38. Park, S.S., and Lee, D. (2007). Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein. Eur. J. Neurosci. 26, 3104-3112.
39. Posser, T., Franco, J.L., dos Santos, D.A., Rigon, A.P., Farina, M., Dafre, A.L., and Leal, R.B. (2008). Diphenyl diselenide confers neuroprotection against hydrogen peroxide toxicity in hippocampal slices. Brain Res. 1199, 138-147.
40. Prediger, R.D., Franco, J.L., Pandolfo, P., Medeiros, R., Duarte, F.S., Di Giunta, G., Figueiredo, C.P., Farina, M., Calixto, J.B., Takahashi, R.N., et al. (2007). Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behav. Brain Res. 177, 205-213.
41. Saberi, B., Shinohara, M., Ybanez, M.D., Hanawa, N., Gaarde, W.A., and Han, D. (2008). Regulation of H2O2-induced necrosis by PKC and AMP activated kinase signaling in primary cultured hepatocytes. Am. J. Physiol. Cell. Physiol. 295, C50-C63.
42. Sarada, S.K., Himadri, P., Ruma, D., Sharma, S.K., and Mrinalini (2008). Selenium protects the hypoxia induced apoptosis in neuroblastoma cells through upregulation of Bcl-2. Brain Res. 1209, 29-39.
43. Shih, A.Y., and Murphy, T.H. (2007). Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells. J. Neurochem. 101, 109-119.
44. Smith, M.P., and Cass, W.A. (2007). Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 144, 1057-1066.
45. Xiao-Qing, T., Jun-Li, Z., Yu, C., and Pei-Xi, C. (2005). Hydrogen peroxide preconditioning protects PC12 cells against apoptosis induced by dopamine. Life Sci. 78, 61-66.
46. Zhang, S., Zou, Z., Jiang, X., Xu, R., Zhang, W., and Ke, Y. (2008). The therapeutic effects of tyrosine hydroxylase gene transfected hematopoetic stem cells in a rat model of Parkinson's disease. Cell. Mol. Neurobiol. 28, 529-543.